NZ553506A - Fused tricyclic derivatives for the treatment of psychotic disorders - Google Patents

Info

Publication number

NZ553506A

NZ553506A NZ553506A NZ55350605A NZ553506A NZ 553506 A NZ553506 A NZ 553506A NZ 553506 A NZ553506 A NZ 553506A NZ 55350605 A NZ55350605 A NZ 55350605A NZ 553506 A NZ553506 A NZ 553506A

Authority

NZ

New Zealand

Prior art keywords

disorder

galkyl

galkoxy

methyl

mmol

Prior art date

2004-08-31

Links

• Espacenet
• Global Dossier
• Discuss

• 208000028017 Psychotic disease Diseases 0.000 title claims description 28
• 238000011282 treatment Methods 0.000 title description 24
• 150000001875 compounds Chemical class 0.000 claims abstract description 449
• 125000001424 substituent group Chemical group 0.000 claims abstract description 53
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
• 150000003839 salts Chemical class 0.000 claims abstract description 48
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 46
• 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 40
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 37
• 201000010099 disease Diseases 0.000 claims abstract description 26
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 24
• 208000035475 disorder Diseases 0.000 claims abstract description 22
• 229910052717 sulfur Inorganic materials 0.000 claims abstract description 14
• 230000000697 serotonin reuptake Effects 0.000 claims abstract description 12
• 230000001404 mediated effect Effects 0.000 claims abstract description 9
• 206010036596 premature ejaculation Diseases 0.000 claims abstract description 9
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
• 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 8
• 239000001301 oxygen Substances 0.000 claims abstract description 8
• 125000005842 heteroatom Chemical group 0.000 claims abstract description 4
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 88
• -1 cyano, nitro, amino Chemical group 0.000 claims description 79
• 229910052736 halogen Inorganic materials 0.000 claims description 66
• 150000002367 halogens Chemical class 0.000 claims description 64
• 229910052739 hydrogen Inorganic materials 0.000 claims description 53
• 239000001257 hydrogen Substances 0.000 claims description 53
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 50
• 239000012458 free base Substances 0.000 claims description 45
• 125000003118 aryl group Chemical group 0.000 claims description 43
• 150000002431 hydrogen Chemical group 0.000 claims description 38
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 28
• 208000019901 Anxiety disease Diseases 0.000 claims description 28
• 206010026749 Mania Diseases 0.000 claims description 25
• 208000019022 Mood disease Diseases 0.000 claims description 24
• 229910052727 yttrium Inorganic materials 0.000 claims description 23
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 22
• 125000003435 aroyl group Chemical group 0.000 claims description 21
• 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 19
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 18
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 18
• 239000002585 base Substances 0.000 claims description 17
• 208000020401 Depressive disease Diseases 0.000 claims description 15
• 208000024714 major depressive disease Diseases 0.000 claims description 15
• 208000019906 panic disease Diseases 0.000 claims description 15
• 208000004230 Gender Dysphoria Diseases 0.000 claims description 13
• 230000003001 depressive effect Effects 0.000 claims description 13
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
• 208000020925 Bipolar disease Diseases 0.000 claims description 12
• 239000003814 drug Substances 0.000 claims description 12
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
• 125000004432 carbon atom Chemical group C* 0.000 claims description 11
• 208000008811 Agoraphobia Diseases 0.000 claims description 10
• 206010033888 Paraphilia Diseases 0.000 claims description 10
• 206010041250 Social phobia Diseases 0.000 claims description 10
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
• 125000005493 quinolyl group Chemical group 0.000 claims description 10
• 208000029810 Gender identity disease Diseases 0.000 claims description 9
• 208000020016 psychiatric disease Diseases 0.000 claims description 9
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 9
• 239000005864 Sulphur Chemical group 0.000 claims description 7
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
• 125000002883 imidazolyl group Chemical group 0.000 claims description 7
• 239000008194 pharmaceutical composition Substances 0.000 claims description 7
• 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 6
• 206010012239 Delusion Diseases 0.000 claims description 6
• 208000004547 Hallucinations Diseases 0.000 claims description 6
• 208000011962 Substance-induced mood disease Diseases 0.000 claims description 6
• 231100000395 Substance-induced mood disorder Toxicity 0.000 claims description 6
• 229910052799 carbon Inorganic materials 0.000 claims description 6
• 125000005724 cycloalkenylene group Chemical group 0.000 claims description 6
• 125000002993 cycloalkylene group Chemical group 0.000 claims description 6
• 231100000868 delusion Toxicity 0.000 claims description 6
• 125000001153 fluoro group Chemical group F* 0.000 claims description 6
• 150000003852 triazoles Chemical group 0.000 claims description 6
• QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 5
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 5
• 208000004483 Dyspareunia Diseases 0.000 claims description 5
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
• 208000021663 Female sexual arousal disease Diseases 0.000 claims description 5
• 206010017389 Frotteurism Diseases 0.000 claims description 5
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
• 206010024419 Libido decreased Diseases 0.000 claims description 5
• 208000030431 Male orgasmic disease Diseases 0.000 claims description 5
• 206010026864 Masochism Diseases 0.000 claims description 5
• 241001465754 Metazoa Species 0.000 claims description 5
• 206010027944 Mood disorder due to a general medical condition Diseases 0.000 claims description 5
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
• 206010033664 Panic attack Diseases 0.000 claims description 5
• 208000032769 Pedophilia Diseases 0.000 claims description 5
• 206010034912 Phobia Diseases 0.000 claims description 5
• 206010039367 Sadism Diseases 0.000 claims description 5
• 208000029901 Sexual arousal disease Diseases 0.000 claims description 5
• 208000030047 Sexual desire disease Diseases 0.000 claims description 5
• 208000027520 Somatoform disease Diseases 0.000 claims description 5
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 5
• 208000026345 acute stress disease Diseases 0.000 claims description 5
• 208000028683 bipolar I disease Diseases 0.000 claims description 5
• 208000022257 bipolar II disease Diseases 0.000 claims description 5
• 208000026725 cyclothymic disease Diseases 0.000 claims description 5
• 208000024732 dysthymic disease Diseases 0.000 claims description 5
• 208000003481 exhibitionism Diseases 0.000 claims description 5
• 208000014840 female orgasmic disease Diseases 0.000 claims description 5
• 206010016531 fetishism Diseases 0.000 claims description 5
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 5
• 208000017020 hypoactive sexual desire disease Diseases 0.000 claims description 5
• 201000004197 inhibited female orgasm Diseases 0.000 claims description 5
• 201000000068 inhibited male orgasm Diseases 0.000 claims description 5
• 208000015421 male orgasm disease Diseases 0.000 claims description 5
• 208000027753 pain disease Diseases 0.000 claims description 5
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
• 230000000306 recurrent effect Effects 0.000 claims description 5
• 125000006413 ring segment Chemical group 0.000 claims description 5
• 208000012201 sexual and gender identity disease Diseases 0.000 claims description 5
• 208000015891 sexual disease Diseases 0.000 claims description 5
• 230000001568 sexual effect Effects 0.000 claims description 5
• 201000005814 sexual masochism Diseases 0.000 claims description 5
• 208000027599 sexual masochism disease Diseases 0.000 claims description 5
• 201000005841 sexual sadism Diseases 0.000 claims description 5
• 208000027596 sexual sadism disease Diseases 0.000 claims description 5
• 201000001716 specific phobia Diseases 0.000 claims description 5
• 201000005142 transvestism Diseases 0.000 claims description 5
• 206010046947 vaginismus Diseases 0.000 claims description 5
• 208000008918 voyeurism Diseases 0.000 claims description 5
• YVLJMJDZPONTBA-UHFFFAOYSA-N 6-[2-[4-(2-methylquinolin-5-yl)piperidin-1-yl]ethyl]imidazo[1,5-a]quinoline-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC2=C(C(N)=O)N=CN2C2=C1C(CCN1CCC(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 YVLJMJDZPONTBA-UHFFFAOYSA-N 0.000 claims description 4
• 206010002859 Anxiety disorder due to a general medical condition Diseases 0.000 claims description 4
• 208000029899 Sexual aversion disease Diseases 0.000 claims description 4
• 125000000217 alkyl group Chemical group 0.000 claims description 4
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
• SLGOOSIRIXMZTP-UHFFFAOYSA-N ethyl 6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]triazolo[1,5-a]quinoline-3-carboxylate;dihydrochloride Chemical compound Cl.Cl.CC1=CC=C2C(N3CCN(CC3)CCC3=C4C=CC=5N(C4=CC=C3)N=NC=5C(=O)OCC)=CC=CC2=N1 SLGOOSIRIXMZTP-UHFFFAOYSA-N 0.000 claims description 4
• 125000001041 indolyl group Chemical group 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 201000000980 schizophrenia Diseases 0.000 claims description 4
• 150000003536 tetrazoles Chemical class 0.000 claims description 4
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
• HLQJZFFWUXHYMB-UHFFFAOYSA-N 6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide Chemical compound O1CC2=C(C(N)=O)N=CN2C2=C1C(CCN1CCN(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 HLQJZFFWUXHYMB-UHFFFAOYSA-N 0.000 claims description 3
• 208000021465 Brief psychotic disease Diseases 0.000 claims description 3
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
• 208000024254 Delusional disease Diseases 0.000 claims description 3
• 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims description 3
• 208000020186 Schizophreniform disease Diseases 0.000 claims description 3
• 208000019568 Shared Paranoid disease Diseases 0.000 claims description 3
• 208000028810 Shared psychotic disease Diseases 0.000 claims description 3
• 206010007776 catatonia Diseases 0.000 claims description 3
• 239000003085 diluting agent Substances 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 3
• 208000022610 schizoaffective disease Diseases 0.000 claims description 3
• 230000000392 somatic effect Effects 0.000 claims description 3
• PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical compound C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 claims description 2
• 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 2
• 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 2
• 125000005647 linker group Chemical group 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 125000004434 sulfur atom Chemical group 0.000 claims description 2
• UIADZDVOONSNAY-UHFFFAOYSA-N 6-[2-[4-(2-methylquinolin-5-yl)piperidin-1-yl]ethyl]triazolo[1,5-a]quinoline-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC2=C(C(N)=O)N=NN2C2=C1C(CCN1CCC(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 UIADZDVOONSNAY-UHFFFAOYSA-N 0.000 claims 3
• WKBJCYVEUPOUTI-GHVWMZMZSA-N 3-methyl-5-[6-[2-[(2r)-2-methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]imidazo[1,5-a]quinolin-3-yl]-1,2,4-oxadiazole;dihydrochloride Chemical compound Cl.Cl.C([C@H]1C)N(C=2C3=CC=C(C)N=C3C=CC=2)CCN1CCC1=CC=CC(N2C=N3)=C1C=CC2=C3C1=NC(C)=NO1 WKBJCYVEUPOUTI-GHVWMZMZSA-N 0.000 claims 2
• ZHRUEMUYDOVBKH-UHFFFAOYSA-N 6-[2-[4-(2-methylquinolin-5-yl)piperidin-1-yl]ethyl]-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC2=C(C(N)=O)N=CN2C2=C1C(CCN1CCC(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 ZHRUEMUYDOVBKH-UHFFFAOYSA-N 0.000 claims 2
• WQPAIWHSXMZKFP-UHFFFAOYSA-N 7-methyl-6-[2-[4-(2-methylquinolin-5-yl)piperidin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.O1CC2=C(C(N)=O)N=CN2C2=C1C(CCN1CCC(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=C(C)C=C2 WQPAIWHSXMZKFP-UHFFFAOYSA-N 0.000 claims 2
• RKWZRKZRPIUILS-UHFFFAOYSA-N 7-methyl-6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxamide Chemical compound C1CC2=C(C(N)=O)N=CN2C2=C1C(CCN1CCN(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=C(C)C=C2 RKWZRKZRPIUILS-UHFFFAOYSA-N 0.000 claims 1
• 206010063659 Aversion Diseases 0.000 claims 1
• 208000027418 Wounds and injury Diseases 0.000 claims 1
• 230000003455 independent Effects 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 108020003175 receptors Proteins 0.000 abstract description 15
• 102000005962 receptors Human genes 0.000 abstract description 15
• 102000035038 5-HT1 receptors Human genes 0.000 abstract description 2
• 108091005478 5-HT1 receptors Proteins 0.000 abstract description 2
• 125000002619 bicyclic group Chemical group 0.000 abstract 1
• 239000011593 sulfur Substances 0.000 abstract 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 399
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 329
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 317
• 239000000203 mixture Substances 0.000 description 207
• 239000000243 solution Substances 0.000 description 203
• 238000001819 mass spectrum Methods 0.000 description 194
• 238000005160 1H NMR spectroscopy Methods 0.000 description 171
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 162
• 239000007787 solid Substances 0.000 description 138
• 229910001868 water Inorganic materials 0.000 description 134
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 125
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 123
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 114
• 235000019439 ethyl acetate Nutrition 0.000 description 107
• 238000000034 method Methods 0.000 description 107
• 239000011541 reaction mixture Substances 0.000 description 105
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 100
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 86
• 238000006243 chemical reaction Methods 0.000 description 82
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 78
• 239000000741 silica gel Substances 0.000 description 76
• 229910002027 silica gel Inorganic materials 0.000 description 76
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
• 239000002904 solvent Substances 0.000 description 54
• 239000012043 crude product Substances 0.000 description 52
• 238000003818 flash chromatography Methods 0.000 description 51
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
• 239000012044 organic layer Substances 0.000 description 48
• 238000003756 stirring Methods 0.000 description 46
• 239000000725 suspension Substances 0.000 description 41
• 238000001704 evaporation Methods 0.000 description 40
• 230000008020 evaporation Effects 0.000 description 40
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
• 239000012074 organic phase Substances 0.000 description 38
• 239000013058 crude material Substances 0.000 description 37
• 229960004132 diethyl ether Drugs 0.000 description 35
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
• 238000010992 reflux Methods 0.000 description 31
• 238000000746 purification Methods 0.000 description 29
• 239000000047 product Substances 0.000 description 28
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 28
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
• 238000004587 chromatography analysis Methods 0.000 description 26
• IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 26
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 25
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
• 229910000027 potassium carbonate Inorganic materials 0.000 description 22
• 229920006395 saturated elastomer Polymers 0.000 description 22
• 238000005481 NMR spectroscopy Methods 0.000 description 21
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 20
• 230000002829 reductive effect Effects 0.000 description 19
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
• 239000003921 oil Substances 0.000 description 18
• 235000019198 oils Nutrition 0.000 description 18
• 238000001665 trituration Methods 0.000 description 18
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 17
• 235000011114 ammonium hydroxide Nutrition 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 16
• 239000002253 acid Substances 0.000 description 16
• 238000010640 amide synthesis reaction Methods 0.000 description 16
• 235000019441 ethanol Nutrition 0.000 description 16
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 15
• 229960000583 acetic acid Drugs 0.000 description 15
• 239000007864 aqueous solution Substances 0.000 description 15
• 238000004128 high performance liquid chromatography Methods 0.000 description 15
• 230000035987 intoxication Effects 0.000 description 15
• 231100000566 intoxication Toxicity 0.000 description 15
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 15
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
• 238000007792 addition Methods 0.000 description 14
• 239000000543 intermediate Substances 0.000 description 14
• 239000012285 osmium tetroxide Substances 0.000 description 14
• 208000019116 sleep disease Diseases 0.000 description 14
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 13
• 238000001914 filtration Methods 0.000 description 13
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 13
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 12
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
• 238000006268 reductive amination reaction Methods 0.000 description 12
• 206010012218 Delirium Diseases 0.000 description 11
• 150000007942 carboxylates Chemical class 0.000 description 11
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 11
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
• 238000001816 cooling Methods 0.000 description 10
• 239000003480 eluent Substances 0.000 description 10
• 239000000377 silicon dioxide Substances 0.000 description 10
• 208000020685 sleep-wake disease Diseases 0.000 description 10
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
• 239000002249 anxiolytic agent Substances 0.000 description 9
• 230000000949 anxiolytic effect Effects 0.000 description 9
• 239000006071 cream Substances 0.000 description 9
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 9
• ODKIQEITOADWNR-UHFFFAOYSA-M potassium;6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound [K+].O1CC2=C(C([O-])=O)N=CN2C2=C1C(CCN1CCN(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 ODKIQEITOADWNR-UHFFFAOYSA-M 0.000 description 9
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
• YIBLESRXXRRDMB-UHFFFAOYSA-N 2-(1-methyl-4h-[1,2,4]triazolo[3,4-c][1,4]benzoxazin-6-yl)acetaldehyde Chemical compound C1=CC=C2N3C(C)=NN=C3COC2=C1CC=O YIBLESRXXRRDMB-UHFFFAOYSA-N 0.000 description 8
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
• 239000008346 aqueous phase Substances 0.000 description 8
• 239000012267 brine Substances 0.000 description 8
• 150000002148 esters Chemical class 0.000 description 8
• 239000012071 phase Substances 0.000 description 8
• 239000002244 precipitate Substances 0.000 description 8
• 239000012312 sodium hydride Substances 0.000 description 8
• 229910000104 sodium hydride Inorganic materials 0.000 description 8
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
• SOGBEZWZAFRXAI-UHFFFAOYSA-N 6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylic acid Chemical compound O1CC2=C(C(O)=O)N=CN2C2=C1C(CCN1CCN(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 SOGBEZWZAFRXAI-UHFFFAOYSA-N 0.000 description 7
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
• 239000012317 TBTU Substances 0.000 description 7
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 7
• RPTWHNIKVTWKSL-UHFFFAOYSA-N ethyl 6-(2-oxoethyl)-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3COC2=C1CC=O RPTWHNIKVTWKSL-UHFFFAOYSA-N 0.000 description 7
• 239000012362 glacial acetic acid Substances 0.000 description 7
• 239000011591 potassium Substances 0.000 description 7
• 229910052700 potassium Inorganic materials 0.000 description 7
• 229940002612 prodrug Drugs 0.000 description 7
• 239000000651 prodrug Substances 0.000 description 7
• RQLAJTRGFNEHAY-UHFFFAOYSA-N tert-butyl 4-(2-formylquinolin-5-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=NC(C=O)=CC=C12 RQLAJTRGFNEHAY-UHFFFAOYSA-N 0.000 description 7
• JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 6
• NWGNXUOYGCERBB-UHFFFAOYSA-N 1-oxido-5-prop-2-enylquinolin-1-ium Chemical compound C1=CC=C2[N+]([O-])=CC=CC2=C1CC=C NWGNXUOYGCERBB-UHFFFAOYSA-N 0.000 description 6
• PZNAAXFCMFHGNR-UHFFFAOYSA-N 2-methyl-5-piperazin-1-ylquinoline Chemical compound C=1C=CC2=NC(C)=CC=C2C=1N1CCNCC1 PZNAAXFCMFHGNR-UHFFFAOYSA-N 0.000 description 6
• QTRAZZDPEITRAG-UHFFFAOYSA-N 5-piperazin-1-yl-2-(trifluoromethyl)quinoline Chemical compound C=1C=CC2=NC(C(F)(F)F)=CC=C2C=1N1CCNCC1 QTRAZZDPEITRAG-UHFFFAOYSA-N 0.000 description 6
• QQOMXKDBGOPCCF-UHFFFAOYSA-N 8-prop-2-enyl-4h-1,4-benzoxazine-3-thione Chemical compound N1C(=S)COC2=C1C=CC=C2CC=C QQOMXKDBGOPCCF-UHFFFAOYSA-N 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
• 229910021529 ammonia Inorganic materials 0.000 description 6
• 235000019270 ammonium chloride Nutrition 0.000 description 6
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 6
• FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 6
• PMRNILNQGXJPSE-UHFFFAOYSA-N ethyl 6-[2-[4-[2-(trifluoromethyl)quinolin-5-yl]piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound FC(F)(F)C1=CC=C2C(N3CCN(CC3)CCC3=C4OCC=5N(C4=CC=C3)C=NC=5C(=O)OCC)=CC=CC2=N1 PMRNILNQGXJPSE-UHFFFAOYSA-N 0.000 description 6
• 230000000147 hypnotic effect Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 229960005235 piperonyl butoxide Drugs 0.000 description 6
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
• 239000000932 sedative agent Substances 0.000 description 6
• 230000001624 sedative effect Effects 0.000 description 6
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• 239000003039 volatile agent Substances 0.000 description 6
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
• OFECTGRBQVWMEK-UHFFFAOYSA-N 1-bromo-4-fluoro-2-prop-2-enoxybenzene Chemical compound FC1=CC=C(Br)C(OCC=C)=C1 OFECTGRBQVWMEK-UHFFFAOYSA-N 0.000 description 5
• JAGNTOYHTNEHKR-UHFFFAOYSA-N 2-(3-bromo-6-fluoro-2-hydroxyphenyl)acetaldehyde Chemical compound OC1=C(Br)C=CC(F)=C1CC=O JAGNTOYHTNEHKR-UHFFFAOYSA-N 0.000 description 5
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
• 206010013654 Drug abuse Diseases 0.000 description 5
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
• 150000001299 aldehydes Chemical class 0.000 description 5
• 229940025084 amphetamine Drugs 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 239000000935 antidepressant agent Substances 0.000 description 5
• 238000004440 column chromatography Methods 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 239000000706 filtrate Substances 0.000 description 5
• 239000007789 gas Substances 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 230000000155 isotopic effect Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 5
• 230000002085 persistent effect Effects 0.000 description 5
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 208000011117 substance-related disease Diseases 0.000 description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
• RQSNCJJYXMNGJM-UHFFFAOYSA-N 1-nitro-2-prop-2-enoxybenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC=C RQSNCJJYXMNGJM-UHFFFAOYSA-N 0.000 description 4
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
• KVNAARREQORWCW-UHFFFAOYSA-N 2-nitro-6-prop-2-enylphenol Chemical compound OC1=C(CC=C)C=CC=C1[N+]([O-])=O KVNAARREQORWCW-UHFFFAOYSA-N 0.000 description 4
• VCVWLRZNGAKWFY-UHFFFAOYSA-N 4-methyl-1-nitro-2-prop-2-enoxybenzene Chemical compound CC1=CC=C([N+]([O-])=O)C(OCC=C)=C1 VCVWLRZNGAKWFY-UHFFFAOYSA-N 0.000 description 4
• ZXNJOUOZRKYALP-UHFFFAOYSA-N 5-prop-2-enyl-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1C=CC=C2CC=C ZXNJOUOZRKYALP-UHFFFAOYSA-N 0.000 description 4
• GGSJHDPHGXYNCW-UHFFFAOYSA-N 6-[3-[4-(2-methylquinolin-5-yl)piperazin-1-yl]propyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylic acid Chemical compound O1CC2=C(C(O)=O)N=CN2C2=C1C(CCCN1CCN(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 GGSJHDPHGXYNCW-UHFFFAOYSA-N 0.000 description 4
• HNQCTKVOLVBTCG-UHFFFAOYSA-N 8-prop-2-enyl-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=C1C=CC=C2CC=C HNQCTKVOLVBTCG-UHFFFAOYSA-N 0.000 description 4
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
• 239000005695 Ammonium acetate Substances 0.000 description 4
• 208000022497 Cocaine-Related disease Diseases 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• 208000003863 Marijuana Abuse Diseases 0.000 description 4
• 208000026251 Opioid-Related disease Diseases 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 235000019257 ammonium acetate Nutrition 0.000 description 4
• 229940043376 ammonium acetate Drugs 0.000 description 4
• 229940005513 antidepressants Drugs 0.000 description 4
• 239000000164 antipsychotic agent Substances 0.000 description 4
• 239000000010 aprotic solvent Substances 0.000 description 4
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
• ULXBTCAXCQWKDE-UHFFFAOYSA-N ethyl 6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound CC1=CC=C2C(N3CCN(CC3)CCC3=C4OCC=5N(C4=CC=C3)C=NC=5C(=O)OCC)=CC=CC2=N1 ULXBTCAXCQWKDE-UHFFFAOYSA-N 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 238000000605 extraction Methods 0.000 description 4
• 150000007857 hydrazones Chemical class 0.000 description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
• 239000002480 mineral oil Substances 0.000 description 4
• 235000010446 mineral oil Nutrition 0.000 description 4
• 239000003960 organic solvent Substances 0.000 description 4
• 150000002923 oximes Chemical class 0.000 description 4
• 208000022821 personality disease Diseases 0.000 description 4
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
• 229950010883 phencyclidine Drugs 0.000 description 4
• 125000004193 piperazinyl group Chemical group 0.000 description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
• 239000012047 saturated solution Substances 0.000 description 4
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
• 235000010265 sodium sulphite Nutrition 0.000 description 4
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
• 229910052725 zinc Inorganic materials 0.000 description 4
• 239000011701 zinc Substances 0.000 description 4
• ZZGQSAVCPDVORI-UHFFFAOYSA-N (2-oxo-3,4-dihydro-1h-quinolin-5-yl) trifluoromethanesulfonate Chemical compound N1C(=O)CCC2=C1C=CC=C2OS(=O)(=O)C(F)(F)F ZZGQSAVCPDVORI-UHFFFAOYSA-N 0.000 description 3
• XVIRIXVOLLJIPF-UHFFFAOYSA-N 1-nitro-2-(2-nitrophenoxy)benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1OC1=CC=CC=C1[N+]([O-])=O XVIRIXVOLLJIPF-UHFFFAOYSA-N 0.000 description 3
• 238000004293 19F NMR spectroscopy Methods 0.000 description 3
• JZWKVWXBFMBHMJ-UHFFFAOYSA-N 2-(7-methyl-3-oxo-4h-1,4-benzoxazin-8-yl)acetaldehyde Chemical compound N1C(=O)COC2=C(CC=O)C(C)=CC=C21 JZWKVWXBFMBHMJ-UHFFFAOYSA-N 0.000 description 3
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
• VYBPMZDJOAFKHJ-UHFFFAOYSA-N 2-[6-bromo-3-fluoro-2-[2-[4-[2-(trifluoromethyl)quinolin-5-yl]piperazin-1-yl]ethyl]phenoxy]acetamide Chemical compound NC(=O)COC1=C(Br)C=CC(F)=C1CCN1CCN(C=2C3=CC=C(N=C3C=CC=2)C(F)(F)F)CC1 VYBPMZDJOAFKHJ-UHFFFAOYSA-N 0.000 description 3
• JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 3
• IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
• 208000031091 Amnestic disease Diseases 0.000 description 3
• 208000029197 Amphetamine-Related disease Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
• 208000006199 Parasomnias Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical compound C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 description 3
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
• FWYINIJABGFVBH-UHFFFAOYSA-N [2-(trifluoromethyl)quinolin-5-yl] trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=CC2=NC(C(F)(F)F)=CC=C21 FWYINIJABGFVBH-UHFFFAOYSA-N 0.000 description 3
• BWYUCZMEDBXLFT-UHFFFAOYSA-N [6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazin-3-yl]-morpholin-4-ylmethanone;dihydrochloride Chemical compound Cl.Cl.C=1C=CC2=NC(C)=CC=C2C=1N(CC1)CCN1CCC1=CC=CC(N2C=N3)=C1OCC2=C3C(=O)N1CCOCC1 BWYUCZMEDBXLFT-UHFFFAOYSA-N 0.000 description 3
• 150000001241 acetals Chemical class 0.000 description 3
• PNNYMZXLAXMKNO-UHFFFAOYSA-N acetic acid;2-methylpiperidin-4-one Chemical compound CC(O)=O.CC1CC(=O)CCN1 PNNYMZXLAXMKNO-UHFFFAOYSA-N 0.000 description 3
• BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 229940005529 antipsychotics Drugs 0.000 description 3
• 229940005530 anxiolytics Drugs 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000000356 contaminant Substances 0.000 description 3
• 230000001351 cycling effect Effects 0.000 description 3
• 150000001934 cyclohexanes Chemical class 0.000 description 3
• 238000010511 deprotection reaction Methods 0.000 description 3
• 235000014632 disordered eating Nutrition 0.000 description 3
• 206010013663 drug dependence Diseases 0.000 description 3
• CVAJBXBSKCQEEL-UHFFFAOYSA-N ethyl 7-fluoro-6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound CC1=CC=C2C(N3CCN(CC3)CCC3=C4OCC=5N(C4=CC=C3F)C=NC=5C(=O)OCC)=CC=CC2=N1 CVAJBXBSKCQEEL-UHFFFAOYSA-N 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 239000000380 hallucinogen Substances 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
• 239000008241 heterogeneous mixture Substances 0.000 description 3
• FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 206010020765 hypersomnia Diseases 0.000 description 3
• 206010022437 insomnia Diseases 0.000 description 3
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
• CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
• YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 239000011347 resin Substances 0.000 description 3
• 229920005989 resin Polymers 0.000 description 3
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 235000010288 sodium nitrite Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 3
• GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
• HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 2
• BLIIGJWCHUYTPO-UHFFFAOYSA-N 1-[6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazin-3-yl]ethanone;hydrochloride Chemical compound Cl.CC1=CC=C2C(N3CCN(CC3)CCC3=C4OCC=5N(C4=CC=C3)C=NC=5C(=O)C)=CC=CC2=N1 BLIIGJWCHUYTPO-UHFFFAOYSA-N 0.000 description 2
• HVGKVHGVVRGKIG-UHFFFAOYSA-N 1-azido-2-but-2-ynoxy-3-prop-2-enylbenzene Chemical compound CC#CCOC1=C(CC=C)C=CC=C1N=[N+]=[N-] HVGKVHGVVRGKIG-UHFFFAOYSA-N 0.000 description 2
• LAMAZVUUAMWNJJ-UHFFFAOYSA-N 1-methoxy-2-(1-methyl-[1,2,4]triazolo[4,3-a]quinolin-6-yl)ethanol Chemical compound C1=CC2=NN=C(C)N2C2=C1C(CC(O)OC)=CC=C2 LAMAZVUUAMWNJJ-UHFFFAOYSA-N 0.000 description 2
• MTRVONGVAYWOAM-UHFFFAOYSA-N 1-methyl-6-prop-2-enyl-[1,2,4]triazolo[4,3-a]quinoline Chemical compound C1=CC=C2N3C(C)=NN=C3C=CC2=C1CC=C MTRVONGVAYWOAM-UHFFFAOYSA-N 0.000 description 2
• QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
• YZBZKLOJMRVJDO-UHFFFAOYSA-N 2-(1-methyl-[1,2,4]triazolo[4,3-a]quinolin-6-yl)acetaldehyde Chemical compound C1=CC=C2N3C(C)=NN=C3C=CC2=C1CC=O YZBZKLOJMRVJDO-UHFFFAOYSA-N 0.000 description 2
• ODMAIPYWWKKKFP-UHFFFAOYSA-N 2-(1-oxo-4h-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-6-yl)acetaldehyde Chemical compound O1CC2=NOC(=O)N2C2=C1C(CC=O)=CC=C2 ODMAIPYWWKKKFP-UHFFFAOYSA-N 0.000 description 2
• RALBDEYJQYKWKN-UHFFFAOYSA-N 2-(2-oxo-3,4-dihydro-1h-quinolin-5-yl)acetaldehyde Chemical compound N1C(=O)CCC2=C1C=CC=C2CC=O RALBDEYJQYKWKN-UHFFFAOYSA-N 0.000 description 2
• LBBPCBSNRAVBOO-UHFFFAOYSA-N 2-(3-methyl-4h-triazolo[5,1-c][1,4]benzoxazin-6-yl)acetaldehyde Chemical compound C1=CC=C2N3N=NC(C)=C3COC2=C1CC=O LBBPCBSNRAVBOO-UHFFFAOYSA-N 0.000 description 2
• HEOGCLJPJQPPFY-UHFFFAOYSA-N 2-(4h-imidazo[5,1-c][1,4]benzoxazin-6-yl)acetaldehyde Chemical compound O1CC2=CN=CN2C2=C1C(CC=O)=CC=C2 HEOGCLJPJQPPFY-UHFFFAOYSA-N 0.000 description 2
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
• MCXZYJWNYYJCAA-UHFFFAOYSA-N 2-[2-bromo-6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]phenoxy]propanamide Chemical compound NC(=O)C(C)OC1=C(Br)C=CC=C1CCN1CCN(C=2C3=CC=C(C)N=C3C=CC=2)CC1 MCXZYJWNYYJCAA-UHFFFAOYSA-N 0.000 description 2
• UAFLLCBXRSMNJV-UHFFFAOYSA-N 2-[3-oxo-4-(3-oxobutan-2-yl)-1,4-benzoxazin-8-yl]acetaldehyde Chemical compound C1=CC=C2N(C(C)C(C)=O)C(=O)COC2=C1CC=O UAFLLCBXRSMNJV-UHFFFAOYSA-N 0.000 description 2
• JXPXLLDYEKAHFZ-UHFFFAOYSA-N 2-bromo-6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]phenol Chemical compound C=1C=CC2=NC(C)=CC=C2C=1N(CC1)CCN1CCC1=CC=CC(Br)=C1O JXPXLLDYEKAHFZ-UHFFFAOYSA-N 0.000 description 2
• YBEOJGOKPDUXFF-UHFFFAOYSA-N 2-but-2-ynoxy-1-nitro-3-prop-2-enylbenzene Chemical compound CC#CCOC1=C(CC=C)C=CC=C1[N+]([O-])=O YBEOJGOKPDUXFF-UHFFFAOYSA-N 0.000 description 2
• GYHIAXVQMYEUBZ-UHFFFAOYSA-N 2-but-2-ynoxy-3-prop-2-enylaniline Chemical compound CC#CCOC1=C(N)C=CC=C1CC=C GYHIAXVQMYEUBZ-UHFFFAOYSA-N 0.000 description 2
• APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
• LSYXNECZRAJSMM-UHFFFAOYSA-N 2-methyl-4-oxopiperidine-1-carboxylic acid Chemical compound CC1CC(=O)CCN1C(O)=O LSYXNECZRAJSMM-UHFFFAOYSA-N 0.000 description 2
• LRJUSAZJVCXDGD-UHFFFAOYSA-N 2-methyl-5-piperidin-4-ylquinoline Chemical compound C=1C=CC2=NC(C)=CC=C2C=1C1CCNCC1 LRJUSAZJVCXDGD-UHFFFAOYSA-N 0.000 description 2
• SCJANADRQMGLBR-UHFFFAOYSA-N 2-methyl-8-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC=C2C(N3CCN(CC3)CCC3=C4OC(C(NC4=CC=C3)=O)C)=CC=CC2=N1 SCJANADRQMGLBR-UHFFFAOYSA-N 0.000 description 2
• OIMRLHCSLQUXLL-UHFFFAOYSA-N 3-chlorobutan-2-one Chemical compound CC(Cl)C(C)=O OIMRLHCSLQUXLL-UHFFFAOYSA-N 0.000 description 2
• KYYGFZNFUJIJPP-UHFFFAOYSA-N 3-methyl-6-nitro-2-prop-2-enylphenol Chemical compound CC1=CC=C([N+]([O-])=O)C(O)=C1CC=C KYYGFZNFUJIJPP-UHFFFAOYSA-N 0.000 description 2
• IMWPGNVKYPMIEA-UHFFFAOYSA-N 3-methyl-6-prop-2-enyl-4h-triazolo[5,1-c][1,4]benzoxazine Chemical compound C1=CC=C2N3N=NC(C)=C3COC2=C1CC=C IMWPGNVKYPMIEA-UHFFFAOYSA-N 0.000 description 2
• WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 2
• ICUSCYLOIDGHRA-UHFFFAOYSA-N 4-(2-oxopropyl)-8-prop-2-enyl-1,4-benzoxazin-3-one Chemical compound C1=CC=C2N(CC(=O)C)C(=O)COC2=C1CC=C ICUSCYLOIDGHRA-UHFFFAOYSA-N 0.000 description 2
• WEKLAXLKDWAFEL-UHFFFAOYSA-N 4-(3-oxobutan-2-yl)-8-prop-2-enyl-1,4-benzoxazin-3-one Chemical compound C1=CC=C2N(C(C)C(C)=O)C(=O)COC2=C1CC=C WEKLAXLKDWAFEL-UHFFFAOYSA-N 0.000 description 2
• HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 2
• QPFXFQDKBBIFTN-UHFFFAOYSA-N 5-prop-2-enyl-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2CC=C QPFXFQDKBBIFTN-UHFFFAOYSA-N 0.000 description 2
• JFIQBMBMQPOKSI-UHFFFAOYSA-N 5-prop-2-enyl-3,4-dihydro-1h-quinoline-2-thione Chemical compound N1C(=S)CCC2=C1C=CC=C2CC=C JFIQBMBMQPOKSI-UHFFFAOYSA-N 0.000 description 2
• BHJDPQOAJYAFLK-UHFFFAOYSA-N 5-prop-2-enylquinoline Chemical compound C1=CC=C2C(CC=C)=CC=CC2=N1 BHJDPQOAJYAFLK-UHFFFAOYSA-N 0.000 description 2
• LRTVHPWDAKVNCW-LJQANCHMSA-N 6-[2-[(2r)-2-methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylic acid Chemical compound CC1=CC=C2C(N3C[C@H](N(CC3)CCC=3C4=C(N5C=NC(=C5CO4)C(O)=O)C=CC=3)C)=CC=CC2=N1 LRTVHPWDAKVNCW-LJQANCHMSA-N 0.000 description 2
• PKWIRIVLJQCGPA-UHFFFAOYSA-N 6-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.O1CC2=C(C(N)=O)N=CN2C2=C1C(CCN1CCN(CC1)C=1C3=CC=C(N=C3C=CC=1)C)=CC=C2 PKWIRIVLJQCGPA-UHFFFAOYSA-N 0.000 description 2
• VVGNCGCOOAXREM-UHFFFAOYSA-N 6-prop-2-enyl-4h-imidazo[2,1-c][1,4]benzoxazine Chemical compound O1CC2=NC=CN2C2=C1C(CC=C)=CC=C2 VVGNCGCOOAXREM-UHFFFAOYSA-N 0.000 description 2
• SVPYOBSKRMZKNY-UHFFFAOYSA-N 6-prop-2-enyl-4h-imidazo[5,1-c][1,4]benzoxazine Chemical compound O1CC2=CN=CN2C2=C1C(CC=C)=CC=C2 SVPYOBSKRMZKNY-UHFFFAOYSA-N 0.000 description 2
• OUZYVEAQCZIROP-UHFFFAOYSA-N 6-prop-2-enyl-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylic acid Chemical compound C1=CC=C2N3C=NC(C(=O)O)=C3COC2=C1CC=C OUZYVEAQCZIROP-UHFFFAOYSA-N 0.000 description 2
• IZZOFFAYDNYUPD-UHFFFAOYSA-N 6-prop-2-enyltetrazolo[1,5-a]quinoline Chemical compound C1=CC2=NN=NN2C2=C1C(CC=C)=CC=C2 IZZOFFAYDNYUPD-UHFFFAOYSA-N 0.000 description 2
• KZEUOISQVQZYQE-UHFFFAOYSA-N 7-fluoro-8-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=C1C=CC(F)=C2CCN(CC1)CCN1C1=CC=CC2=NC(C)=CC=C21 KZEUOISQVQZYQE-UHFFFAOYSA-N 0.000 description 2
• AYWJIVPXLGWXLW-UHFFFAOYSA-N 7-fluoro-8-[2-[4-[2-(trifluoromethyl)quinolin-5-yl]piperazin-1-yl]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound FC(F)(F)C1=CC=C2C(N3CCN(CC3)CCC3=C4OCC(=O)NC4=CC=C3F)=CC=CC2=N1 AYWJIVPXLGWXLW-UHFFFAOYSA-N 0.000 description 2
• SHVPFLFHXJWSQB-UHFFFAOYSA-N 7-methyl-8-prop-2-enyl-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=C(CC=C)C(C)=CC=C21 SHVPFLFHXJWSQB-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• HBUZMXCDGGXCGT-UHFFFAOYSA-N 8-(3-hydroxypropyl)-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=C1C=CC=C2CCCO HBUZMXCDGGXCGT-UHFFFAOYSA-N 0.000 description 2
• REMGWKNJHLCDCD-UHFFFAOYSA-N 8-but-3-en-2-yl-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=C1C=CC=C2C(C=C)C REMGWKNJHLCDCD-UHFFFAOYSA-N 0.000 description 2
• 206010000117 Abnormal behaviour Diseases 0.000 description 2
• 206010001605 Alcohol poisoning Diseases 0.000 description 2
• 208000007848 Alcoholism Diseases 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• 241000218236 Cannabis Species 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 208000017781 Cocaine intoxication Diseases 0.000 description 2
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
• 206010013980 Dyssomnias Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 208000030814 Eating disease Diseases 0.000 description 2
• 208000019454 Feeding and Eating disease Diseases 0.000 description 2
• 206010016754 Flashback Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• 239000001828 Gelatine Substances 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 206010057672 Male sexual dysfunction Diseases 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 208000028505 alcohol-related disease Diseases 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 239000000908 ammonium hydroxide Substances 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 208000029560 autism spectrum disease Diseases 0.000 description 2
• NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
• 208000014679 binge eating disease Diseases 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 229960001948 caffeine Drugs 0.000 description 2
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
• 201000001843 cannabis dependence Diseases 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000002843 carboxylic acid group Chemical group 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 229960003920 cocaine Drugs 0.000 description 2
• 239000010779 crude oil Substances 0.000 description 2
• 239000012045 crude solution Substances 0.000 description 2
• KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 230000000694 effects Effects 0.000 description 2
• IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 description 2
• UMTDVVYLUYYZKA-UHFFFAOYSA-N ethyl 2-amino-2-(5-prop-2-enylquinolin-2-yl)acetate Chemical compound C=CCC1=CC=CC2=NC(C(N)C(=O)OCC)=CC=C21 UMTDVVYLUYYZKA-UHFFFAOYSA-N 0.000 description 2
• GPSHPDLSGLNKQL-UHFFFAOYSA-N ethyl 2-nitro-2-(5-prop-2-enylquinolin-2-yl)acetate Chemical compound C=CCC1=CC=CC2=NC(C(C(=O)OCC)[N+]([O-])=O)=CC=C21 GPSHPDLSGLNKQL-UHFFFAOYSA-N 0.000 description 2
• FTKASJMIPSSXBP-UHFFFAOYSA-N ethyl 2-nitroacetate Chemical compound CCOC(=O)C[N+]([O-])=O FTKASJMIPSSXBP-UHFFFAOYSA-N 0.000 description 2
• KSYXFRVYGOXWDP-UHFFFAOYSA-N ethyl 6-(2-oxoethyl)imidazo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3C=CC2=C1CC=O KSYXFRVYGOXWDP-UHFFFAOYSA-N 0.000 description 2
• VALMBXODVHTTPV-UHFFFAOYSA-N ethyl 6-(3-oxopropyl)-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3COC2=C1CCC=O VALMBXODVHTTPV-UHFFFAOYSA-N 0.000 description 2
• OISVWLCCAJDSMA-UHFFFAOYSA-N ethyl 6-(trifluoromethylsulfonyloxy)-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3CCC2=C1OS(=O)(=O)C(F)(F)F OISVWLCCAJDSMA-UHFFFAOYSA-N 0.000 description 2
• KDRFSQVOSMTVGH-OAQYLSRUSA-N ethyl 6-[2-[(2r)-2-methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound CC1=CC=C2C(N3CCN([C@@H](C3)C)CCC3=C4OCC=5N(C4=CC=C3)C=NC=5C(=O)OCC)=CC=CC2=N1 KDRFSQVOSMTVGH-OAQYLSRUSA-N 0.000 description 2
• FHQYSSAGWGZKMN-UHFFFAOYSA-N ethyl 6-[2-[4-(2-methylquinazolin-5-yl)piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound CC1=NC=C2C(N3CCN(CC3)CCC3=C4OCC=5N(C4=CC=C3)C=NC=5C(=O)OCC)=CC=CC2=N1 FHQYSSAGWGZKMN-UHFFFAOYSA-N 0.000 description 2
• BZGQSDFVMIEUKH-UHFFFAOYSA-N ethyl 6-[tert-butyl(dimethyl)silyl]oxy-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3CCC2=C1O[Si](C)(C)C(C)(C)C BZGQSDFVMIEUKH-UHFFFAOYSA-N 0.000 description 2
• UAMHVYPHTVBXHG-UHFFFAOYSA-N ethyl 6-but-3-en-2-yl-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3COC2=C1C(C)C=C UAMHVYPHTVBXHG-UHFFFAOYSA-N 0.000 description 2
• BMLJPJIDABQWLS-UHFFFAOYSA-N ethyl 6-hydroxy-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3CCC2=C1O BMLJPJIDABQWLS-UHFFFAOYSA-N 0.000 description 2
• VYXBDKCPUKFGMY-UHFFFAOYSA-N ethyl 6-prop-2-enyl-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3CCC2=C1CC=C VYXBDKCPUKFGMY-UHFFFAOYSA-N 0.000 description 2
• MXGGDSOPVLIRDC-UHFFFAOYSA-N ethyl 6-prop-2-enylimidazo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3C=NC(C(=O)OCC)=C3C=CC2=C1CC=C MXGGDSOPVLIRDC-UHFFFAOYSA-N 0.000 description 2
• CHLGLIJPGARJCK-UHFFFAOYSA-N ethyl 7-fluoro-6-[2-[4-[2-(trifluoromethyl)quinolin-5-yl]piperazin-1-yl]ethyl]-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound FC(F)(F)C1=CC=C2C(N3CCN(CC3)CCC3=C4OCC=5N(C4=CC=C3F)C=NC=5C(=O)OCC)=CC=CC2=N1 CHLGLIJPGARJCK-UHFFFAOYSA-N 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 230000004907 flux Effects 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000005227 gel permeation chromatography Methods 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 208000011331 hallucinogen-persisting perception disease Diseases 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 150000005826 halohydrocarbons Chemical class 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• VCKSKMPUHSKTNE-UHFFFAOYSA-N methyl 2-(2-but-3-en-2-yl-6-nitrophenoxy)acetate Chemical compound COC(=O)COC1=C(C(C)C=C)C=CC=C1[N+]([O-])=O VCKSKMPUHSKTNE-UHFFFAOYSA-N 0.000 description 2
• NICDEUUBCKPMLW-UHFFFAOYSA-N methyl 2-(2-nitro-6-prop-2-enylphenoxy)acetate Chemical compound COC(=O)COC1=C(CC=C)C=CC=C1[N+]([O-])=O NICDEUUBCKPMLW-UHFFFAOYSA-N 0.000 description 2
• VYGXTDHYEXEDGP-UHFFFAOYSA-N methyl 2-(3-methyl-6-nitro-2-prop-2-enylphenoxy)acetate Chemical compound COC(=O)COC1=C(CC=C)C(C)=CC=C1[N+]([O-])=O VYGXTDHYEXEDGP-UHFFFAOYSA-N 0.000 description 2
• FLQZVDOGOMPTKG-UHFFFAOYSA-N methyl 2-(3-oxo-8-prop-2-enyl-1,4-benzoxazin-4-yl)acetate Chemical compound C1=CC=C2N(CC(=O)OC)C(=O)COC2=C1CC=C FLQZVDOGOMPTKG-UHFFFAOYSA-N 0.000 description 2
• 229960004503 metoclopramide Drugs 0.000 description 2
• TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 229940127237 mood stabilizer Drugs 0.000 description 2
• 239000012299 nitrogen atmosphere Substances 0.000 description 2
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
• 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 238000007248 oxidative elimination reaction Methods 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 208000007100 phencyclidine abuse Diseases 0.000 description 2
• 235000011056 potassium acetate Nutrition 0.000 description 2
• CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 230000001376 precipitating effect Effects 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 238000010926 purge Methods 0.000 description 2
• DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
• LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 2
• BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 2
• 229960003770 reboxetine Drugs 0.000 description 2
• CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 2
• 239000004576 sand Substances 0.000 description 2
• JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• HQMYWQCBINPHBB-UHFFFAOYSA-N tert-butyl 2-methyl-4-oxopiperidine-1-carboxylate Chemical compound CC1CC(=O)CCN1C(=O)OC(C)(C)C HQMYWQCBINPHBB-UHFFFAOYSA-N 0.000 description 2
• PYCPZPRHJAHUQK-UHFFFAOYSA-N tert-butyl 4-(2-cyanoquinolin-5-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=NC(C#N)=CC=C12 PYCPZPRHJAHUQK-UHFFFAOYSA-N 0.000 description 2
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
• 229960003604 testosterone Drugs 0.000 description 2
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
• 229960000604 valproic acid Drugs 0.000 description 2
• 229960004688 venlafaxine Drugs 0.000 description 2
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
• 239000008215 water for injection Substances 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
• IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
• WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 description 1
• FGFKSBOBRKEBRK-UHFFFAOYSA-N (2-methylquinolin-5-yl) trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=CC2=NC(C)=CC=C21 FGFKSBOBRKEBRK-UHFFFAOYSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
• FOUUFYVJZJXAJH-UHFFFAOYSA-N (5-prop-2-enylquinolin-2-yl)hydrazine Chemical compound C1=CC=C2NC(=NN)C=CC2=C1CC=C FOUUFYVJZJXAJH-UHFFFAOYSA-N 0.000 description 1
• NCCUEFAMFFQHNU-UHFFFAOYSA-N (6-methyl-2-oxo-3,4-dihydro-1h-quinolin-5-yl) trifluoromethanesulfonate Chemical compound N1C(=O)CCC2=C(OS(=O)(=O)C(F)(F)F)C(C)=CC=C21 NCCUEFAMFFQHNU-UHFFFAOYSA-N 0.000 description 1
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
• ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
• UQPSYCCVESDKKX-UHFFFAOYSA-N (Z)-4H-1,2-benzoxazin-3-ylidenehydrazine Chemical compound C1=CC=C2CC(NN)=NOC2=C1 UQPSYCCVESDKKX-UHFFFAOYSA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• FBZVZUSVGKOWHG-UHFFFAOYSA-N 1,1-dimethoxy-n,n-dimethylethanamine Chemical compound COC(C)(OC)N(C)C FBZVZUSVGKOWHG-UHFFFAOYSA-N 0.000 description 1
• CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 1
• WENXBAFANCRIGK-UHFFFAOYSA-N 1-bromonaphthalen-2-amine Chemical compound C1=CC=CC2=C(Br)C(N)=CC=C21 WENXBAFANCRIGK-UHFFFAOYSA-N 0.000 description 1
• ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
• CMOKUAFPPCEHHF-UHFFFAOYSA-N 1-hydroxy-3-methylurea Chemical compound CNC(=O)NO CMOKUAFPPCEHHF-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• RZQQXRVPPOOCQR-UHFFFAOYSA-N 2,3-dihydro-1,3,4-oxadiazole Chemical compound C1NN=CO1 RZQQXRVPPOOCQR-UHFFFAOYSA-N 0.000 description 1
• HGYBLJOLKSUUEQ-UHFFFAOYSA-N 2-(3-bromo-2-hydroxyphenyl)acetaldehyde Chemical compound OC1=C(Br)C=CC=C1CC=O HGYBLJOLKSUUEQ-UHFFFAOYSA-N 0.000 description 1
• ZQORUXPSYCZIFV-UHFFFAOYSA-N 2-(4h-imidazo[2,1-c][1,4]benzoxazin-6-yl)acetaldehyde Chemical compound O1CC2=NC=CN2C2=C1C(CC=O)=CC=C2 ZQORUXPSYCZIFV-UHFFFAOYSA-N 0.000 description 1
• MKLZSDOGVXVHTQ-UHFFFAOYSA-N 2-(trifluoromethyl)quinolin-5-ol Chemical compound FC(F)(F)C1=CC=C2C(O)=CC=CC2=N1 MKLZSDOGVXVHTQ-UHFFFAOYSA-N 0.000 description 1
• NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 1
• SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
• HUVAOAVBKOVPBZ-UHFFFAOYSA-N 2-bromo-5-fluorophenol Chemical compound OC1=CC(F)=CC=C1Br HUVAOAVBKOVPBZ-UHFFFAOYSA-N 0.000 description 1
• PTJOFMJOMTXHGU-UHFFFAOYSA-N 2-bromo-6-prop-2-enylphenol Chemical compound OC1=C(Br)C=CC=C1CC=C PTJOFMJOMTXHGU-UHFFFAOYSA-N 0.000 description 1
• VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
• AUHYZQCEIVEMFH-UHFFFAOYSA-N 2-bromopropanamide Chemical compound CC(Br)C(N)=O AUHYZQCEIVEMFH-UHFFFAOYSA-N 0.000 description 1
• PLFGZBNKKXCKMO-UHFFFAOYSA-N 2-fluoro-5-(5-propylpyridin-2-yl)aniline Chemical compound N1=CC(CCC)=CC=C1C1=CC=C(F)C(N)=C1 PLFGZBNKKXCKMO-UHFFFAOYSA-N 0.000 description 1
• XOGIRAQPVLKDBV-KIYNQFGBSA-N 2-methyl-1-[(1s)-1-phenylethyl]piperidin-4-one Chemical compound N1([C@@H](C)C=2C=CC=CC=2)CCC(=O)CC1C XOGIRAQPVLKDBV-KIYNQFGBSA-N 0.000 description 1
• VYJMNRHPDWSKAJ-UHFFFAOYSA-N 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline Chemical compound C=1C=CC2=NC(C)=CC=C2C=1B1OC(C)(C)C(C)(C)O1 VYJMNRHPDWSKAJ-UHFFFAOYSA-N 0.000 description 1
• UJEYHIWKFIXAEE-UHFFFAOYSA-N 2-methyl-5-phenyl-2,3-dihydro-1h-pyridine-6-thione Chemical compound S=C1NC(C)CC=C1C1=CC=CC=C1 UJEYHIWKFIXAEE-UHFFFAOYSA-N 0.000 description 1
• MPKLQDHWNDPEOG-UHFFFAOYSA-N 2-methyl-5-piperazin-1-ylquinazoline Chemical compound C=1C=CC2=NC(C)=NC=C2C=1N1CCNCC1 MPKLQDHWNDPEOG-UHFFFAOYSA-N 0.000 description 1
• NCKUDHXUEUXBEH-UHFFFAOYSA-N 2-methyl-6-prop-2-enyl-4h-[1,2,4]triazolo[3,4-c][1,4]benzoxazin-1-one Chemical compound C1OC2=C(CC=C)C=CC=C2N2C1=NN(C)C2=O NCKUDHXUEUXBEH-UHFFFAOYSA-N 0.000 description 1
• SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
• FUZKRNSSYGNAMF-UHFFFAOYSA-N 2-methylsulfanyl-5-prop-2-enyl-3,4-dihydroquinoline Chemical compound C1=CC(CC=C)=C2CCC(SC)=NC2=C1 FUZKRNSSYGNAMF-UHFFFAOYSA-N 0.000 description 1
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
• ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
• IVUYQNXYKGKHQN-UHFFFAOYSA-N 4-[[4-(diethylamino)phenyl]-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)methyl]-1,5-dimethyl-2-phenylpyrazol-3-one Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C(N(C=2C=CC=CC=2)N(C)C=1C)=O)C(C1=O)=C(C)N(C)N1C1=CC=CC=C1 IVUYQNXYKGKHQN-UHFFFAOYSA-N 0.000 description 1
• JEUAWMJVEYFVNJ-UHFFFAOYSA-N 5-Aminoacenaphthene Chemical compound C1CC2=CC=CC3=C2C1=CC=C3N JEUAWMJVEYFVNJ-UHFFFAOYSA-N 0.000 description 1
• LPNMGOIBVCQLIP-UHFFFAOYSA-N 5-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]quinoline-2-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=NC(C(O)=O)=CC=C12 LPNMGOIBVCQLIP-UHFFFAOYSA-N 0.000 description 1
• CHONOBMGSBMLDE-UHFFFAOYSA-N 5-bromo-6-methylquinoline Chemical compound N1=CC=CC2=C(Br)C(C)=CC=C21 CHONOBMGSBMLDE-UHFFFAOYSA-N 0.000 description 1
• CHODTZCXWXCALP-UHFFFAOYSA-N 5-bromoquinoline Chemical compound C1=CC=C2C(Br)=CC=CC2=N1 CHODTZCXWXCALP-UHFFFAOYSA-N 0.000 description 1
• LDMHLWVMDQGTCA-UHFFFAOYSA-N 5-hydroxy-6-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C(O)C(C)=CC=C21 LDMHLWVMDQGTCA-UHFFFAOYSA-N 0.000 description 1
• XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
• LYRFHQXQXXNQST-UHFFFAOYSA-N 6-methyl-5-prop-2-enyl-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C(CC=C)C(C)=CC=C21 LYRFHQXQXXNQST-UHFFFAOYSA-N 0.000 description 1
• QKSLNZAHNWBHFK-UHFFFAOYSA-N 6-methyl-5-prop-2-enylquinoline Chemical compound N1=CC=CC2=C(CC=C)C(C)=CC=C21 QKSLNZAHNWBHFK-UHFFFAOYSA-N 0.000 description 1
• QJTQYMOXDJCLSJ-UHFFFAOYSA-N 6-prop-2-enyl-4,5-dihydrotetrazolo[1,5-a]quinoline Chemical compound C1CC2=NN=NN2C2=C1C(CC=C)=CC=C2 QJTQYMOXDJCLSJ-UHFFFAOYSA-N 0.000 description 1
• YXANKZJGJNSBJU-UHFFFAOYSA-N 7-bromo-4-fluoro-2,3-dihydro-1-benzofuran-2-ol Chemical compound BrC1=CC=C(F)C2=C1OC(O)C2 YXANKZJGJNSBJU-UHFFFAOYSA-N 0.000 description 1
• SUMCLKYERGMWOE-UHFFFAOYSA-N 7-fluoro-2-methyl-5-piperazin-1-ylquinoline Chemical compound C=1C(F)=CC2=NC(C)=CC=C2C=1N1CCNCC1 SUMCLKYERGMWOE-UHFFFAOYSA-N 0.000 description 1
• DSRZHYGLARQICV-UHFFFAOYSA-N 8-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=C1C=CC=C2CCN(CC1)CCN1C1=CC=CC2=NC(C)=CC=C21 DSRZHYGLARQICV-UHFFFAOYSA-N 0.000 description 1
• 206010001596 Alcohol induced persisting dementia Diseases 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 206010004716 Binge eating Diseases 0.000 description 1
• 208000021500 Breathing-related sleep disease Diseases 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
• 101100316805 Caenorhabditis elegans spe-5 gene Proteins 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 208000027691 Conduct disease Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
• 206010012225 Delirium tremens Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
• 239000004150 EU approved colour Substances 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 206010057671 Female sexual dysfunction Diseases 0.000 description 1
• PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
• 208000010235 Food Addiction Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 239000007818 Grignard reagent Substances 0.000 description 1
• 208000016619 Histrionic personality disease Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000001271 Inhalant Abuse Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
• UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
• WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
• UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
• KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 208000027120 Narcissistic personality disease Diseases 0.000 description 1
• 206010057852 Nicotine dependence Diseases 0.000 description 1
• 208000000224 Night Terrors Diseases 0.000 description 1
• 206010029412 Nightmare Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
• RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000034592 Polysubstance dependence Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 208000006289 Rett Syndrome Diseases 0.000 description 1
• 208000036353 Rett disease Diseases 0.000 description 1
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
• 208000030988 Schizoid Personality disease Diseases 0.000 description 1
• 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 239000004141 Sodium laurylsulphate Substances 0.000 description 1
• 239000004283 Sodium sorbate Substances 0.000 description 1
• 206010041347 Somnambulism Diseases 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• 231100000643 Substance intoxication Toxicity 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
• GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
• 208000025569 Tobacco Use disease Diseases 0.000 description 1
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
• BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
• JNMSWINOHOQWQE-UHFFFAOYSA-N [2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-benzofuran-4-yl] trifluoromethanesulfonate Chemical compound O1C(C)=NN=C1C1=CC2=C(OS(=O)(=O)C(F)(F)F)C=CC=C2O1 JNMSWINOHOQWQE-UHFFFAOYSA-N 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• ZVDDJPSHRNMSKV-UHFFFAOYSA-N acetaldehyde;hydrochloride Chemical compound Cl.CC=O ZVDDJPSHRNMSKV-UHFFFAOYSA-N 0.000 description 1
• 159000000021 acetate salts Chemical class 0.000 description 1
• OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 150000001266 acyl halides Chemical class 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 208000029650 alcohol withdrawal Diseases 0.000 description 1
• 208000006246 alcohol withdrawal delirium Diseases 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
• 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
• 229960004538 alprazolam Drugs 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229960000711 alprostadil Drugs 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 238000005576 amination reaction Methods 0.000 description 1
• 229960003036 amisulpride Drugs 0.000 description 1
• NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 201000002472 amphetamine abuse Diseases 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 229960003116 amyl nitrite Drugs 0.000 description 1
• 239000003263 anabolic agent Substances 0.000 description 1
• 229940070021 anabolic steroids Drugs 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 208000024823 antisocial personality disease Diseases 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 229960004046 apomorphine Drugs 0.000 description 1
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• 208000022804 avoidant personality disease Diseases 0.000 description 1
• 125000002785 azepinyl group Chemical group 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
• 229960001081 benzatropine Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 150000001557 benzodiazepines Chemical class 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 150000005130 benzoxazines Chemical class 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 229960003003 biperiden Drugs 0.000 description 1
• YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
• 208000030963 borderline personality disease Diseases 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• DFFDSQBEGQFJJU-UHFFFAOYSA-M butyl carbonate Chemical compound CCCCOC([O-])=O DFFDSQBEGQFJJU-UHFFFAOYSA-M 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 201000009322 cannabis abuse Diseases 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 150000001793 charged compounds Chemical class 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 208000024825 childhood disintegrative disease Diseases 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 229960001653 citalopram Drugs 0.000 description 1
• 229960004606 clomipramine Drugs 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 201000001272 cocaine abuse Diseases 0.000 description 1
• 201000006145 cocaine dependence Diseases 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 239000002475 cognitive enhancer Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000012050 conventional carrier Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 235000019788 craving Nutrition 0.000 description 1
• YTKRILODNOEEPX-NSCUHMNNSA-N crotyl chloride Chemical compound C\C=C\CCl YTKRILODNOEEPX-NSCUHMNNSA-N 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000005725 cyclohexenylene group Chemical group 0.000 description 1
• 125000004956 cyclohexylene group Chemical group 0.000 description 1
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
• NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 238000006114 decarboxylation reaction Methods 0.000 description 1
• 230000003226 decolorizating effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 208000030964 dependent personality disease Diseases 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 125000003963 dichloro group Chemical group Cl* 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 229960000520 diphenhydramine Drugs 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• HXJFQNUWPUICNY-UHFFFAOYSA-N disiamylborane Chemical compound CC(C)C(C)BC(C)C(C)C HXJFQNUWPUICNY-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229960002866 duloxetine Drugs 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 229960004341 escitalopram Drugs 0.000 description 1
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 229940052303 ethers for general anesthesia Drugs 0.000 description 1
• UIMYPNYOSDSJKK-UHFFFAOYSA-N ethyl 2-(5-prop-2-enylquinolin-2-yl)acetate Chemical compound C=CCC1=CC=CC2=NC(CC(=O)OCC)=CC=C21 UIMYPNYOSDSJKK-UHFFFAOYSA-N 0.000 description 1
• PEXDISSPMWNCGO-UHFFFAOYSA-N ethyl 2-(6-methyl-5-prop-2-enylquinolin-2-yl)-2-nitroacetate Chemical compound C=CCC1=C(C)C=CC2=NC(C(C(=O)OCC)[N+]([O-])=O)=CC=C21 PEXDISSPMWNCGO-UHFFFAOYSA-N 0.000 description 1
• VZPRMNPINIAWPF-UHFFFAOYSA-N ethyl 6-prop-2-enyl-4h-triazolo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound C1=CC=C2N3N=NC(C(=O)OCC)=C3COC2=C1CC=C VZPRMNPINIAWPF-UHFFFAOYSA-N 0.000 description 1
• CKUXXWSNOIHEOG-UHFFFAOYSA-N ethyl 6-prop-2-enyltriazolo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3N=NC(C(=O)OCC)=C3C=CC2=C1CC=C CKUXXWSNOIHEOG-UHFFFAOYSA-N 0.000 description 1
• GVIISALLXQBMHJ-UHFFFAOYSA-N ethyl 7-methyl-6-prop-2-enyl-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxylate Chemical compound CC1=CC=C2N3C=NC(C(=O)OCC)=C3CCC2=C1CC=C GVIISALLXQBMHJ-UHFFFAOYSA-N 0.000 description 1
• ADAFWHDNWYMBFI-UHFFFAOYSA-N ethyl 7-methyl-6-prop-2-enylimidazo[1,5-a]quinoline-3-carboxylate Chemical compound CC1=CC=C2N3C=NC(C(=O)OCC)=C3C=CC2=C1CC=C ADAFWHDNWYMBFI-UHFFFAOYSA-N 0.000 description 1
• XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
• AXCAVQGOBCIZTD-UHFFFAOYSA-N ethyl n-[(8-prop-2-enyl-2h-1,4-benzoxazin-3-yl)amino]carbamate Chemical compound C1=CC(CC=C)=C2OCC(NNC(=O)OCC)=NC2=C1 AXCAVQGOBCIZTD-UHFFFAOYSA-N 0.000 description 1
• VYSYZMNJHYOXGN-UHFFFAOYSA-N ethyl n-aminocarbamate Chemical compound CCOC(=O)NN VYSYZMNJHYOXGN-UHFFFAOYSA-N 0.000 description 1
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000003885 eye ointment Substances 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 229950003930 femoxetine Drugs 0.000 description 1
• OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012065 filter cake Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• 229960002690 fluphenazine Drugs 0.000 description 1
• 229960004038 fluvoxamine Drugs 0.000 description 1
• CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• 229960003980 galantamine Drugs 0.000 description 1
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
• 229960003727 granisetron Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 150000004795 grignard reagents Chemical class 0.000 description 1
• 201000002270 hallucinogen abuse Diseases 0.000 description 1
• 201000006138 hallucinogen dependence Diseases 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229960004801 imipramine Drugs 0.000 description 1
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
• 229950002473 indalpine Drugs 0.000 description 1
• SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 229960002672 isocarboxazid Drugs 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
• 229960001848 lamotrigine Drugs 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 229960004391 lorazepam Drugs 0.000 description 1
• 229960000423 loxapine Drugs 0.000 description 1
• YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
• 229960004090 maprotiline Drugs 0.000 description 1
• QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
• 229960000300 mesoridazine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• ZQBMKMZGWKGAHQ-UHFFFAOYSA-N methyl 2-(5-prop-2-enylquinolin-2-yl)acetate Chemical compound C=CCC1=CC=CC2=NC(CC(=O)OC)=CC=C21 ZQBMKMZGWKGAHQ-UHFFFAOYSA-N 0.000 description 1
• MLGFAMKMKXUWIN-UHFFFAOYSA-N methyl 3-oxo-2-(5-prop-2-enylquinolin-2-yl)butanoate Chemical compound C=CCC1=CC=CC2=NC(C(C(C)=O)C(=O)OC)=CC=C21 MLGFAMKMKXUWIN-UHFFFAOYSA-N 0.000 description 1
• SMWZXNACRLAVOP-UHFFFAOYSA-N methyl 6-prop-2-enyltriazolo[1,5-a]quinoline-3-carboxylate Chemical compound C1=CC=C2N3N=NC(C(=O)OC)=C3C=CC2=C1CC=C SMWZXNACRLAVOP-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical compound CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 229960003955 mianserin Drugs 0.000 description 1
• 229960000600 milnacipran Drugs 0.000 description 1
• 229960001785 mirtazapine Drugs 0.000 description 1
• RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
• 229960004644 moclobemide Drugs 0.000 description 1
• 229960004938 molindone Drugs 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
• 239000004223 monosodium glutamate Substances 0.000 description 1
• 239000004050 mood stabilizer Substances 0.000 description 1
• ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
• DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
• NTMHWRHEGDRTPD-UHFFFAOYSA-N n-(4-azidosulfonylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(S(=O)(=O)N=[N+]=[N-])C=C1 NTMHWRHEGDRTPD-UHFFFAOYSA-N 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• XHFGWHUWQXTGAT-UHFFFAOYSA-N n-methylpropan-2-amine Chemical compound CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 229960001800 nefazodone Drugs 0.000 description 1
• VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• 239000001272 nitrous oxide Substances 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 229960001158 nortriptyline Drugs 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 229960005017 olanzapine Drugs 0.000 description 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
• XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
• 229940055577 oleyl alcohol Drugs 0.000 description 1
• 229960005343 ondansetron Drugs 0.000 description 1
• 201000005040 opiate dependence Diseases 0.000 description 1
• 201000000988 opioid abuse Diseases 0.000 description 1
• 208000024196 oppositional defiant disease Diseases 0.000 description 1
• 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
• 239000010502 orange oil Substances 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 238000005949 ozonolysis reaction Methods 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 208000024817 paranoid personality disease Diseases 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 229960002296 paroxetine Drugs 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 229960000762 perphenazine Drugs 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960000964 phenelzine Drugs 0.000 description 1
• 229960001999 phentolamine Drugs 0.000 description 1
• MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Chemical group 0.000 description 1
• XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 229960003111 prochlorperazine Drugs 0.000 description 1
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
• 229960005253 procyclidine Drugs 0.000 description 1
• 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• 125000003410 quininyl group Chemical group 0.000 description 1
• DJXNJVFEFSWHLY-UHFFFAOYSA-M quinoline-3-carboxylate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-M 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• BLGXFZZNTVWLAY-DIRVCLHFSA-N rauwolscine Chemical compound C1=CC=C2C(CCN3C[C@H]4CC[C@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-DIRVCLHFSA-N 0.000 description 1
• 239000003507 refrigerant Substances 0.000 description 1
• 239000013557 residual solvent Substances 0.000 description 1
• 239000002151 riboflavin Substances 0.000 description 1
• 235000019192 riboflavin Nutrition 0.000 description 1
• 229960001534 risperidone Drugs 0.000 description 1
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
• 229960004136 rivastigmine Drugs 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 230000013275 serotonin uptake Effects 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 229960002073 sertraline Drugs 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
• 229940084026 sodium valproate Drugs 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 231100000736 substance abuse Toxicity 0.000 description 1
• 201000006152 substance dependence Diseases 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
• 229960003708 sumatriptan Drugs 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 229960001685 tacrine Drugs 0.000 description 1
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• COWVSHYGRCIMEK-UHFFFAOYSA-N tert-butyl 2-methyl-4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC1CC(OS(=O)(=O)C(F)(F)F)=CCN1C(=O)OC(C)(C)C COWVSHYGRCIMEK-UHFFFAOYSA-N 0.000 description 1
• ZLIUDOJYYSHFCI-UHFFFAOYSA-N tert-butyl 4-(2-methylquinolin-5-yl)piperazine-1-carboxylate Chemical compound C=1C=CC2=NC(C)=CC=C2C=1N1CCN(C(=O)OC(C)(C)C)CC1 ZLIUDOJYYSHFCI-UHFFFAOYSA-N 0.000 description 1
• PQBGBNWEAZJROW-UHFFFAOYSA-N tert-butyl 4-[2-(difluoromethyl)quinolin-5-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=NC(C(F)F)=CC=C12 PQBGBNWEAZJROW-UHFFFAOYSA-N 0.000 description 1
• ZOSUWLAWHQBTAI-UHFFFAOYSA-N tert-butyl 4-[2-(dimethylcarbamoyl)quinolin-5-yl]piperazine-1-carboxylate Chemical compound C=1C=CC2=NC(C(=O)N(C)C)=CC=C2C=1N1CCN(C(=O)OC(C)(C)C)CC1 ZOSUWLAWHQBTAI-UHFFFAOYSA-N 0.000 description 1
• IVDOHYRTEUTYHL-UHFFFAOYSA-N tert-butyl 4-[2-(fluoromethyl)quinolin-5-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=NC(CF)=CC=C12 IVDOHYRTEUTYHL-UHFFFAOYSA-N 0.000 description 1
• RHYOYFFQGZYRCY-UHFFFAOYSA-N tert-butyl 4-[2-(hydroxymethyl)quinolin-5-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=NC(CO)=CC=C12 RHYOYFFQGZYRCY-UHFFFAOYSA-N 0.000 description 1
• KFLKGZMTYDWMJK-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-quinolin-5-ylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C1=CC=CC2=NC=CC=C12 KFLKGZMTYDWMJK-UHFFFAOYSA-N 0.000 description 1
• ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000007970 thio esters Chemical class 0.000 description 1
• 150000003555 thioacetals Chemical class 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• 229960002784 thioridazine Drugs 0.000 description 1
• PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
• 229960001918 tiagabine Drugs 0.000 description 1
• 208000016686 tic disease Diseases 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229960004394 topiramate Drugs 0.000 description 1
• CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 229960003741 tranylcypromine Drugs 0.000 description 1
• 229960003991 trazodone Drugs 0.000 description 1
• PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
• CGYSOCLEJCQMLB-UHFFFAOYSA-N triazolo[1,5-a]quinoline-3-carboxamide dihydrochloride Chemical compound C1=CC=C2C(=C1)C=CC3=C(N=NN32)C(=O)N.Cl.Cl CGYSOCLEJCQMLB-UHFFFAOYSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 229960002324 trifluoperazine Drugs 0.000 description 1
• ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
• 229960001032 trihexyphenidyl Drugs 0.000 description 1
• SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
• 229960002431 trimipramine Drugs 0.000 description 1
• ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 238000009827 uniform distribution Methods 0.000 description 1
• 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960002381 vardenafil Drugs 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229960000317 yohimbine Drugs 0.000 description 1
• BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
• AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
• 229960002791 zimeldine Drugs 0.000 description 1
• OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1